The clinical analysis of small cell lung cancer treatment with recombinant human endostatin injection and cis-platinum complexes
10.3760/cma.j.issn.1008-6706.2012.12.004
- VernacularTitle:重组人血管内皮抑制素联合顺铂治疗小细胞肺癌的临床分析
- Author:
Xiuli DAI
;
Aihong DONG
;
Dongmei SUN
- Publication Type:Journal Article
- Keywords:
Carcinoma;
small cell;
Endostatin;
Cis-platinum
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(12):1767-1768
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of small cell lung cancer(SCLC) treatment with recombinant human endostatin injection and cis-platinum complexes.Methods 100 patients with SCLC were divided into 2groups.The experiment group used cis-platinum complexes while the control group used recombinant human endostatin injection.Results The effective rate of experiment group was obviously higher than the control group ( 74.0％ vs60.0％,x2=2.16,P ＜ 0.05 ).The median survival time of experiment group was better than control group( t=2.02,P ＜ 0.05 ).The diverse of untoward effect of two groups had no difference ( P ＞ 0.05).Conclusion Recombinant human endostatin injection and cis-platinum complexes were better therapy for SCLC,which had stable effect,no severe untoward effect and overcome the drug-fast of cis-platinum complexes.
